CMS said in its latest Medicare Drug Price Negotiation Program guidance it still working on a process to allow manufacturers to avoid providing a 340B price and a negotiated fair price for the same drug.
340B Issues Remain Unresolved in Latest CMS Medicare Drug Price Negotiation Guidance